Most people on Wegovy lose between 10% and 15% of their body weight within the first year. In clinical trials, participants lost an average of 14.9% of their starting weight over about 16 months. In real-world use, where adherence is less consistent, the average drops to around 7.7% at one year. The gap between those numbers comes down to whether you stay on the medication, reach the full dose, and make dietary changes alongside it.
What Clinical Trials Show
The main Wegovy trials enrolled adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related health condition like high blood pressure or type 2 diabetes. Over 68 weeks (roughly 16 months), participants taking the standard 2.4 mg maintenance dose lost an average of 14.9% of their body weight, compared to about 2.4% in the placebo group. A newer trial testing a higher 7.2 mg dose found even greater losses of 18.7%, though that dose isn’t yet standard.
To put that in practical terms: if you weigh 220 pounds, a 15% loss means about 33 pounds over 16 months. At 250 pounds, you’re looking at roughly 37 pounds. At 300 pounds, around 45 pounds.
What Real-World Results Look Like
Clinical trial participants receive regular check-ins, dietary counseling, and consistent medication supply, which inflates their results compared to typical patients. A large real-world study of over 6,400 people found the average weight loss with semaglutide (Wegovy’s active ingredient) was 7.7% at one year, about half the trial figure.
The biggest factor was whether people stuck with treatment. Those who continued taking Wegovy at full maintenance doses lost 13.7% at one year, very close to trial results. People who stopped early lost far less: 5.8% for those who quit later in treatment and just 2.9% for those who discontinued early. Staying on the medication and reaching the highest tolerated dose is what separates a modest result from a significant one.
The Weight Loss Timeline
Wegovy uses a gradual dose escalation over the first 16 weeks to reduce side effects. You start at a low dose and increase every four weeks until reaching the maintenance level. Weight loss follows this same slow ramp:
- Weeks 1 to 4: About 2% of body weight, as you’re on the lowest dose and your body is adjusting.
- Weeks 5 to 8: Around 4% total. You may start noticing reduced appetite more consistently.
- Weeks 9 to 12: Roughly 6% total. This is when many people say the medication “clicks” and food noise quiets down.
- Weeks 13 to 16: About 8% total, as you approach the full maintenance dose.
- Weeks 17 to 21: Weight loss accelerates once you’re on the maintenance dose, with some data showing up to 17% total by this point.
- Beyond week 21: Losses can reach 20% or more, though results vary widely between individuals.
The first month often feels underwhelming. You may lose only a few pounds and wonder if the medication is working. That’s normal and by design. The dose escalation exists to let your gut adjust gradually.
How Wegovy Produces Weight Loss
Wegovy mimics a hormone called GLP-1 that your body naturally releases after eating. It works through two main pathways. First, it activates receptors in the brain regions that control hunger and fullness, dialing down appetite so you feel satisfied with smaller portions and experience fewer cravings between meals. Second, it slows the speed at which food leaves your stomach, so meals keep you feeling full for longer.
The combined effect is that most people simply eat less without the constant mental battle of willpower. Many users describe a quieting of “food noise,” that persistent background thinking about what to eat next. The medication doesn’t eliminate hunger entirely, but it changes the volume dial significantly.
Side Effects During the Ramp-Up
Gastrointestinal side effects are common, especially during the dose escalation period. Nausea is the most frequent complaint, followed by diarrhea, vomiting, and constipation. These symptoms are generally temporary and tend to ease as your body adjusts to each new dose level.
About 4.3% of people in trials stopped Wegovy entirely because of gut-related side effects: 1.8% due to nausea, 1.2% due to vomiting, and 0.7% due to diarrhea. That means roughly 95 out of 100 people were able to tolerate the medication well enough to continue. Eating smaller meals, avoiding fatty or greasy foods, and staying hydrated during the titration period can help manage symptoms.
What Happens If You Stop
This is the part most people don’t want to hear. A systematic review published in The BMJ found that people who stop taking newer weight loss medications like Wegovy regain an average of 0.8 kg (about 1.8 pounds) per month after stopping. That adds up to roughly 22 pounds regained in the first year off the medication, with a projected return to baseline weight about 1.5 years after stopping.
This doesn’t mean the medication “didn’t work.” It means obesity is a chronic condition, and Wegovy manages it the way blood pressure medication manages hypertension. The weight loss persists as long as the treatment continues. If you’re considering Wegovy, it helps to think of it as a long-term commitment rather than a temporary fix. Some people use it to lose weight and then transition to lifestyle changes or a lower dose for maintenance, but the data on weight regain is clear: most people need ongoing treatment to keep the weight off.
Factors That Affect Your Results
Individual results vary more than the averages suggest. Some people lose 20% or more, while others plateau around 5%. Several factors influence where you land on that spectrum.
Starting weight matters, but not in the way you might expect. People with higher BMIs often lose more total pounds but a similar percentage of body weight. Diet and exercise make a meaningful difference on top of the medication’s effects. Wegovy is FDA-approved specifically for use alongside a reduced-calorie diet and increased physical activity, and participants in clinical trials received both. Your metabolic history also plays a role. People with type 2 diabetes tend to lose less weight on GLP-1 medications than those without diabetes, likely because insulin resistance affects how the body responds.
Perhaps the most important factor is simply whether you reach and stay on the full maintenance dose. The real-world data makes this strikingly clear: people who maintained high doses lost 13.7%, while early discontinuers lost under 3%. Supply issues, cost, and insurance coverage are real barriers that can interrupt treatment and directly impact outcomes.